Results 91 to 100 of about 57,472 (341)
Frontiers in ImmunologyAngiosarcomas are sporadic vascular neoplasms among the most aggressive subtypes of soft tissue sarcomas. In addition, vast and multiple recurrent superficial scalp and facial angiosarcomas are very complex and extremely difficult to manage.
Ewetse Paul Maswikiti +15 more
doaj +1 more source
Potential therapeutic targeting of BKCa channels in glioblastoma treatment
Molecular Oncology, EarlyView.This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak +4 more
wiley +1 more source
Giant lipoma arising from deep lobe of the parotid gland
World Journal of Surgical Oncology, 2006 Background Lipomas are common benign soft tissue neoplasms but they are found very rarely in the deep lobe of parotid gland. Surgical intervention in these tumors is challenging because of the proximity of the facial nerve, and thus knowledge of the ...
Hsu Ying-Che +5 more
doaj +1 more source
Neuronavigational approach for orbital neurofibroma excision: a case report [PDF]
, 2015 Orbital neurofibromas are uncommon in adults, accounting for approximately 1%-3% of all space occupying lesions of the orbit. The complex anatomy of the orbital region, with the pronounced vulnerability of its neurovascular structures, requires ...
CASCONE, PIERO +5 more
core +1 more source
Reliability of the ‘M-Line’ in the Prediction of the Facial Nerve Position in Patients with Parotid Neoplasms [PDF]
, 2021 Pei Fen Cheah +5 more
openalex +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]
, 2020 Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J +3 more
core
A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Molecular Oncology, EarlyView.Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti +3 more
wiley +1 more source
Hemangiosarcoma of the third eyelid in a horse [PDF]
, 2009 A 12-year-old Belgian Warmblood mare was referred to the equine clinic of the Faculty of Veterinary Medicine (Ghent University) for a mass on the third eyelid of the right eye. The horse had been having a recurrent red-tinged ocular discharge for several
Chiers, Koen +4 more
core
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source